Richard Scolyer

Professor Richard Scolyer BMedSci, MBBS, MD, FRCPA, FRCPath, FAHMS is Senior Staff Specialist, Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney; Co- Medical Director, Melanoma Institute Australia[1]; and Clinical Professor, The University of Sydney.[2]

Prof Richard Scolyer

He provides a clinical consultation service for the diagnosis of difficult pigmented lesions and receives more than 2000 cases for opinion from Australasia and beyond annually. Scolyer effectively integrates his clinical practice with leading an award winning translational melanoma research laboratory.[1]

His record includes co-authoring more than 700 publications/book-chapters including in prestigious journals such as New England Journal of Medicine, Lancet, Nature, Cell, Nature Genetics, Lancet Oncology, Journal of Clinical Oncology, Journal of the National Cancer Institute and Cancer Discovery with >37,800 citations. Scolyer has presented on more than 350 occasions at conferences throughout the world.[1]

He received a NSW Premier's Award for Outstanding Cancer Research in 2009, 2012, 2013, 2014, 2016, 2017 and 2018[3], Thomson Reuters 2015 Citation Award in the Clinical Medicine category, the 2018 William O. Russell/Joanne Vandenberge Hill Award for Lifetime Achievement in Anatomical Pathology, MD Anderson Cancer Center, Research Australia’s 2018 GSK Award for Research Excellence, the 2019 American Society of Dermatopathology’s Elson B Helwig Award for excellence in dermatopathology[4] and The University of Sydney’s 2020 International Alumni Award[5]. His publications have received most highly cited awards on 5 other occasions. Recently, Scolyer was recognised as a Clarivate Web of Science “Highly Cited Researcher 2019”.[6] According to Thomson Reuters ISI Web of Knowledge, Richard is the highest ever published scientist in the world in the field of melanoma pathology and he also has the highest H index in this field.[7] The Fame Report (2011) published by Medical Experts International ranked him the 6th leading melanoma expert in any field or discipline worldwide and the highest ranked melanoma pathologist worldwide. In February 2019, he was ranked the world’s 10th leading melanoma expert in any field or discipline and the world’s leading melanoma pathologist.[8] In September 2019, Scolyer was ranked as the leading Australian Pathologist in the entire field of Pathology. [9] In July 2020, he was selected as a finalist for The Pathologist’s 2020 Power List within the “Big Breakthroughs” category, which celebrates trailblazers working at the cutting edge and driving onward the future of the field.[10]

Scolyer was an editor of the 4th Edition of the World Health Organisation Classification of Tumours (Skin Tumours volume)[11] in which he was the responsible editor for 3 of the 6 sections and authored/co-authored more than 30 chapters. He has also been an invited contributing author to 6 other volumes of the WHO Classification of Tumours including for Soft Tissue and Bone, Digestive System, Thoracic, Female Genital Tract and Paediatric tumours.[12]

He is also Vice Chair of the Melanoma Expert Panel of the American Joint Committee on Cancer (AJCC) for the 8th edition of AJCC Cancer Staging System, co-leads the Australian Melanoma Genome Project (part of the International Cancer Genome Consortium), was lead pathologist for the NIH funded The Cancer Genome Atlas (TCGA) Melanoma Project (Cell, 2015), chairs the Melanoma Expert Panel for the International Collaboration on Cancer Reporting, and lead pathologist/member of the overseeing Management Committee, Multidisciplinary Working Party and Author for the Australian Melanoma Clinical Practice Guidelines and co-lead author of the College of American Pathologists Melanoma Reporting protocol. He is also an editorial board member of the American Journal of Surgical Pathology, Modern Pathology and Histopathology and several other international journals and Senior Associate Editor of Pathology. Scolyer is a Past President of the Australasian Division of the International Academy of Pathology and is the current International Vice President representing Australasian on the International Academy of Pathology International Council. In 2019, Scolyer was the RCPA visting Professor/Lecturer to Asia. Together with his MIA colleagues, Scolyer has been chief investigator on 3 consecutive 5 year NHMRC program grants and has received multiple personal Fellowships from the NHMRC and CINSW. He has also been an investigator/advisor on multiple phase 1, 2 and 3 clinical trials and a frequently sort-after advisor to industry.[1]

References
  1. "Our team". Melanoma Institute Australia. Retrieved 2020-08-13.
  2. "Staff Profile". The University of Sydney. Retrieved 2020-08-13.
  3. "NSW Premier's Awards for Outstanding Cancer Research".
  4. "ASDP - Elson B. Helwig Memorial Lecture". www.asdp.org. Retrieved 2020-08-13.
  5. "Graduates shaping the world: Alumni Awards winners 2020". The University of Sydney. Retrieved 2020-08-13.
  6. "Highly Cited Researchers". publons.com. Retrieved 2020-08-13.
  7. "Richard A Scolyer - Google Scholar". scholar.google.com.au. Retrieved 2020-08-13.
  8. "Melanoma: Worldwide - Expertscape.com". expertscape.com. Retrieved 2020-08-13.
  9. "Finding hidden talent | League of Scholars". www.leagueofscholars.com. Retrieved 2020-08-13.
  10. "The Power List 2020". The Pathologist. Retrieved 2020-08-13.
  11. DE, Elder; D, Massi; RA, Scolyer; R, Willemze. WHO Classification of Skin Tumours. ISBN 978-92-832-2440-2.
  12. "IARC Publications Website - WHO Classification of Tumours". publications.iarc.fr. Retrieved 2020-08-13.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.